ISRG slips to $559.44 intraday on NASDAQ 02 Jan 2026: watch AI-enabled growth catalyst
ISRG (Intuitive Surgical, Inc.) opened lower and trades at USD 559.44 intraday on NASDAQ on 02 Jan 2026, down 2.30% from the previous close. The pullback follows mixed flows and insider selling despite robust fundamentals: trailing EPS USD 7.53 and a price-to-earnings ratio near 75.21. For AI stocks investors, Intuitive’s expanding AI and endoluminal platforms are the key growth drivers to watch. Meyka AI-powered market analysis platform flags short-term volatility but sees structural upside tied to product adoption and recurring instrument sales in the United States and international markets.
Intraday price action
ISRG trades at USD 559.44 with a one-day change of -13.19 (or -2.30%).
Today’s range is USD 555.40 to USD 567.39 on volume 690672.00 versus average volume 2030747.00, showing lighter trading and muted conviction.
Fundamentals and valuation
Intuitive Surgical, Inc. reports EPS USD 7.53 and a trailing PE of 75.21, reflecting premium valuation for high margin recurring revenue.
Key ratios include price-to-sales 21.05, price-to-book 11.93 and free cash flow per share USD 6.37, supporting capital allocation for R&D and buybacks. Current market cap is USD 202321048423.00 and cash per share is USD 13.77, leaving the balance sheet liquid.
AI and product growth outlook
Intuitive’s da Vinci platform and Ion endoluminal system are strategic channels for AI-driven workflow and diagnostics that could expand procedure volume.
Revenue growth accelerated to 17.24% year-over-year in the latest fiscal update and R&D sits at 13.04% of revenue, underlining continued investment in software and AI-enabled tools.
Analyst consensus and price targets
Wall Street shows a Moderate Buy consensus: 14 Buys, 2 Holds and 2 Sells in the most recent tally.
Analyst price targets range from USD 525.00 to USD 685.00 with a consensus target of USD 602.76 and median USD 603.00. For context, Goldman Sachs and Sanford Bernstein are among firms with targets above USD 620.00 MarketBeat and price coverage can move intraday Yahoo Finance.
Technicals and trading signals
Short-term indicators are neutral: RSI 52.30 and MACD histogram slightly negative at -0.64.
Bollinger Bands sit at upper USD 586.89 and lower USD 544.76, suggesting current price is inside the band and volatility (ATR 9.96) is moderate for an established large-cap medical device stock.
Meyka grade and model forecast
Meyka AI rates ISRG with a score out of 100: Score 80.64 | Grade A | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a monthly target of USD 607.53 and a yearly target of USD 526.34. Relative to the current price USD 559.44, the monthly projection implies an upside of 8.60% while the yearly projection implies a downside of -5.74%. Forecasts are model-based projections and not guarantees. These outputs complement the analyst consensus target USD 602.76 shown above.
Final Thoughts
Key takeaways for ISRG stock: Intuitive Surgical, Inc. trades at USD 559.44 on NASDAQ intraday 02 Jan 2026 after a modest pullback, with fundamentals anchored by EPS USD 7.53, high gross margin 66.41% and free cash flow per share USD 6.37. Valuation remains premium with a PE near 75.21 but is matched by strong margin conversion and a cash-rich balance sheet. Analyst consensus target sits at USD 602.76 while Meyka AI’s forecast model projects USD 607.53 over the next month, implying an 8.60% upside from current levels. For AI stocks investors, the investment case depends on continued adoption of AI-enabled workflow tools and instrument sales growth against near-term execution and valuation risk. We cite institutional ownership above 83.64% and active insider selling as near-term catalysts to monitor. This analysis is informational and not investment advice.
FAQs
ISRG is trading at USD 559.44 intraday on NASDAQ on 02 Jan 2026, down about -2.30% from the previous close of USD 572.63 at the time of this report.
Meyka AI rates ISRG with a score out of 100: 80.64 (Grade A | Suggestion: BUY). The grade balances benchmark, sector, growth, metrics and analyst views but is informational only.
Analyst targets range from USD 525.00 to USD 685.00 with a consensus target of USD 602.76 and median USD 603.00, reflecting a Moderate Buy consensus from recent coverage.
Intuitive is integrating AI into surgical workflow and diagnostics, backed by R&D spend near 13.04% of revenue. AI tools aim to increase utilization and expand addressable procedures, supporting recurring instrument sales.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
